PLK1 and laryngotracheoesophageal cleft: Enhancing the immunotherapeutic outcome of current immunotherapy using NPs in LC has also been explored through the preparation of a combinatorial chemotherapy/immunotherapy Polo-like kinase 1 (PLK1) inhibitor (Volasertib)—loaded mesoporous silica NPs decorated with an PD-L1 antibody.